香港股市 已收市

PFE Oct 2024 15.000 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
13.95-0.20 (-1.41%)
市場開市。 截至 09:33AM EDT。
全螢幕
前收市價14.15
開市13.95
買盤13.35
賣出價14.05
拍板15.00
到期日2024-10-18
今日波幅13.95 - 13.95
合同範圍
成交量10
未平倉合約32
  • Benzinga

    European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech

    Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the Covid-19 vaccine. The EPO’s Opposition Division upheld the validity of one of Moderna’s crucial patents, boosting the mRNA vaccine maker’s efforts to reclaim pandemic profits from its competitors, the Financial Times reports. Although Pfizer has nine months to appeal the decision, the EPO’s writte

  • Zacks

    Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

    Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

  • Benzinga

    Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game

    On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year’s “Choose France” business summit. Together with the domestic Sanofi (NASDAQ: SNY), Pfizer, AstraZeneca will together invest €1.87 billion which is more than $2 billion to expand their operations in the country. AstraZeneca committed 365 million euros, which is about $394 mi